These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 18626277)

  • 1. Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study.
    Strous RD; Gibel A; Maayan R; Weizman A; Ritsner MS
    J Clin Psychopharmacol; 2008 Aug; 28(4):456-9. PubMed ID: 18626277
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial.
    Ko YH; Lew YM; Jung SW; Joe SH; Lee CH; Jung HG; Lee MS
    J Clin Psychopharmacol; 2008 Aug; 28(4):375-83. PubMed ID: 18626263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone and gonadotropins but not estrogen associated with spatial ability in women suffering from schizophrenia: a double-blind, placebo-controlled study.
    Bergemann N; Parzer P; Kaiser D; Maier-Braunleder S; Mundt C; Klier C
    Psychoneuroendocrinology; 2008 May; 33(4):507-16. PubMed ID: 18343039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium in chronic schizophrenia.
    Growe GA; Crayton JW; Klass DB; Evans H; Strizich M
    Am J Psychiatry; 1979 Apr; 136(4A):454-5. PubMed ID: 34327
    [No Abstract]   [Full Text] [Related]  

  • 9. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer antipsychotics similar to older agents.
    J Fam Pract; 2005 Dec; 54(12):1026. PubMed ID: 16370079
    [No Abstract]   [Full Text] [Related]  

  • 11. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
    Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.
    Emsley R; Niehaus DJ; Oosthuizen PP; Koen L; Ascott-Evans B; Chiliza B; van Rensburg SJ; Smit RM
    Psychiatry Res; 2008 Dec; 161(3):284-91. PubMed ID: 18962989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):923-31. PubMed ID: 19424093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with dehydroepiandrosterone therapy in intrinsic steroid-dependent bronchial asthma].
    Koó E; Fehér GK; Fehér T; Füst G
    Orv Hetil; 1987 Sep; 128(38):1995-7. PubMed ID: 2959897
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic lupus erythematosus.
    Bonney RC
    Am Clin Lab; 2001 Aug; 20(7):18-20. PubMed ID: 11570269
    [No Abstract]   [Full Text] [Related]  

  • 18. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.
    Mössner R; Schuhmacher A; Kühn KU; Cvetanovska G; Rujescu D; Zill P; Quednow BB; Rietschel M; Wölwer W; Gaebel W; Wagner M; Maier W
    Pharmacogenet Genomics; 2009 Jan; 19(1):91-4. PubMed ID: 18849890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.